Bremelanotide (PT-141 and Vyleesi)

Vyleesi is for acquired, generalized hypoactive sexual desire disorder causing distress, when the condition is not explained by other medical or psychiatric causes, relationship problems or substances. It is not labeled as an erectile-dysfunction medicine or a general performance enhancer. ^{1, 2}

Blood-pressure increases and heart-rate decreases are relevant; uncontrolled hypertension and known cardiovascular disease are contraindications. Nausea, flushing, headache and injection-site reactions can occur. Skin darkening is another labeled concern and may persist. Vyleesi can reduce exposure to oral naltrexone used for addiction treatment. ^{1, 2}

A vial or nasal product marketed as PT-141 is not established as Vyleesi by the ingredient name. Ask whether the actual preparation is approved or compounded, what population its evidence addresses, and what medical screening supports the intended use. This draft does not verify Sipra availability.

Bremelanotide can temporarily increase blood pressure and reduce heart rate after use. Vyleesi is contraindicated in uncontrolled high blood pressure or known cardiovascular disease. Blood pressure should be controlled and cardiovascular risk considered before treatment. Severe headache, chest symptoms, fainting or neurologic symptoms require prompt assessment. This safety framework belongs to the evaluated autoinjector and indication; it should not be transferred to an unverified PT-141 vial, nasal product or compounded combination. ^{1, 2}

Nausea is common and can be severe, especially early in use. The label also warns that focal darkening of the face, gums and breasts can occur and may not resolve after stopping; risk appears greater with more frequent exposure and darker skin. A follow-up should review blood pressure, nausea, skin changes and whether the patient's distress and desire have meaningfully improved. If there is no benefit after the labeled evaluation period, continued exposure deserves reassessment. ^{1, 2}

The autoinjector is a single-use prescription device with product-specific storage and administration instructions. Do not reuse it or transfer directions to a vial. The label limits frequency because closely repeated use can increase blood-pressure exposure and adverse effects; the prescriber should explain those limits without relying on memory from an advertisement. Vyleesi is not approved for men, postmenopausal women, performance enhancement or treatment of other sexual dysfunction. A diagnosis still requires attention to medicines, pain, mood and relationship context. ^{1, 2}

Exposure can be higher and last longer in severe kidney impairment and moderate or severe liver impairment. Those conditions require product-specific assessment rather than simply spacing injections by memory. Tell the prescriber about dialysis, reduced kidney function, liver disease and all medicines. Persistent nausea can also reduce fluid intake, so dizziness, low urine output or inability to keep fluids down deserves clinical advice. ²